This technology identifies EGFR and IL-6 as therapeutic targets for the treatment of liver fibrosis and glucose intolerance.
Current treatment strategies for metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis rely primarily on lifestyle modifications, often inadequate and ineffective for patients with advanced disease. There are currently no FDA-approved therapies for MASH. Existing therapeutic approaches primarily target metabolic dysfunctions, but the pathogenesis of the disease is multifactorial, with chronic inflammation also playing an important role. Regulatory T (Treg) cells help maintain tissue homeostasis by limiting inflammation and promoting repair, representing a potential therapeutic modality for halting or reversing disease progression.
The technology identifies a functional relationship between regulatory T (Treg) cells and tissue injury in metabolic dysfunction-associated steatohepatitis (MASH). Treg cells drive hepatic glucose intolerance and liver fibrosis through the secretion of amphiregulin (Areg), an EGFR-ligand that activates hepatic fibroblasts and increases their production of interleukin-6 (IL-6), a pro-inflammatory cytokine. Inhibition of EGFR and IL-6 expression within hepatic stellate cells leverages this relationship to slow the progression of tissue injury and fibrosis. Therefore, the crosstalk between Treg cells and hepatic fibroblasts represents a therapeutic target for the treatment of chronic liver disease and glucose resistance.
This technology has been validated in vitro and in vivo.
Patent Pending (WO/2024/158827)
IR CU23130
Licensing Contact: Cynthia Lang